Sci. STKE, 2 January 2007
Immunology What's in a Vaccine?
Science, AAAS, Washington, DC 20005, USA
After vaccination, the efficiency with which protective antibodies are produced often depends on the presence of an adjuvant, a substance that promotes activation of antibody-producing B cells. It has been anticipated that Toll-like receptors (TLRs) might be major players in mediating the effects of adjuvants. However, Gavin et al. now find that the known TLR pathways do not modulate B cell responses, and so adjuvants containing TLR ligands must depend on other properties. Such a revision to thinking about the effects of TLR on B cell responses will likely refocus current thinking about vaccine development.
A. L. Gavin, K. Hoebe, B. Duong, T. Ota, C. Martin, B. Beutler, D. Nemazee, Adjuvant-enhanced antibody responses in the absence of Toll-like receptor signaling. Science 314, 1936-1938 (2006). [Abstract] [Full Text]
Citation: S. Simpson, What's in a Vaccine? Sci. STKE 2007, tw7 (2007).
Science Signaling. ISSN 1937-9145 (online), 1945-0877 (print). Pre-2008: Science's STKE. ISSN 1525-8882